Louis Garguilo

ARTICLES BY LOUIS

  • How To Get Saved By A Drug Supply Chain
    How To Get Saved By A Drug Supply Chain

    "We’re there to help service providers continue to be healthy, viable businesses,” says Phil RobertsSenior Vice President, Technical Operations, Orexigen. “I’m open to the concept that a static CDMO, is really a dead CDMO,” he concludes. But for Orexigen and its supply chain, it’s been much more of a mutually assured existence. Here’s part two of the journey. 

  • Every Company Tells A Story: Orexigen, Anti-Obesity And Outsourcing
    Every Company Tells A Story: Orexigen, Anti-Obesity And Outsourcing

    Just like with pictures, every company tells a story. For its true grit and determination in the face of regulatory and market adversity, and its survival due to the ability to quickly establish a commercial supply chain and work with outsourcing partners, no company tells us a better story than Orexigen.

  • Unleash Blockchain Technologies On The Entire Supply Chain
    Unleash Blockchain Technologies On The Entire Supply Chain

    Release blockchain technologies from the jaws of serialization. Unleash it on tech transfer, data integrity, project management, supply-chain relationships, and all components that make up our drug development and manufacturing outsourcing industry.

  • Less Cost And More Control Limits Supply Chain Success
    Less Cost And More Control Limits Supply Chain Success

    Our industry would benefit from the sourcing function focusing less on narrow cost reductions, and more on broader corporate objectives; and from drug owners who allow external partners more control of their own environments. These would add up to a better functioning supply chain, and improved overall business outcomes.  

  • 4 Tech Transfer Keys For CMC Success
    4 Tech Transfer Keys For CMC Success

    Let’s look at two practical activities for tech transfer to CDMOs, and two pieces of just as practical advice for working with those service providers, all four to help you increase your Chemistry, Manufacturing and Control (CMC) effectiveness. 

  • The Practice Of Interdisciplinary CMC
    The Practice Of Interdisciplinary CMC

    CMC stands for chemistry, manufacturing and controls, part of any new pharmaceutical product application to the FDA. How virtuals, biotechs, and pharma companies get through the nicely arrayed acronym to an IND or NDA is no easy task. Industry veteran David Hennings says it helps to practice “interdisciplinary CMC.”

  • Platform Or Perish: 9 Steps To Better Partnerships
    Platform Or Perish: 9 Steps To Better Partnerships

    Companies in every industry are defining their next generation of value chains. In doing so, they are increasingly integrating with third parties, and their platforms. Savvy leaders leverage these relationships to unlock their next waves of strategic growth. Here are 9 steps to move the process forward, based on a new report from Accenture. 

  • You Decide: Technologies Impacting Drug Development And Manufacturing
    You Decide: Technologies Impacting Drug Development And Manufacturing

    Quickly: What three technologies impact your drug development and manufacturing? How do those technologies impact your outsourcing partners, processes, and decisions? Thanks for joining today’s flash mind exercise. You’ve also joined executives on the Outsourced Pharma Editorial Advisory Board who did the same. Let’s compare.

  • New Report Helps Forecast Next 5 Years Of Outsourcing
    New Report Helps Forecast Next 5 Years Of Outsourcing

    Discerning growth opportunities (or business contractions) in the drug development and manufacturing outsourcing space is a challenging exercise. Among other things, it requires reading between the lines of various industry reports concentrating otherwise, for example on comparing commercial product sales and R&D pipelines. An “otherwise” focused report worth our attention is the EvaluatePharma World Preview 2017, Outlook to 2022

  • Channeling Socrates With The FDA On Innovative Technologies
    Channeling Socrates With The FDA On Innovative Technologies

    Paraphrasing Henry Hoppe of Xenetic Bioscience, companies on the bleeding edge of innovative technology in drug development and manufacturing should treat visits to the FDA more like Socratic dialogues than stressful duels. Mark Butchko, who’s charted over a decade with Lilly, advises holding some of those dialogues during “pre-operational visits,” or POVs.

Louis Garguilo

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.